Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Dr ...

Core Insights - Apyx Medical Corporation reported a 19% increase in Surgical Aesthetics revenue for Q3 2025, driven by the successful commercialization of the AYON Body Contouring System [3][9] - The company anticipates further growth in sales following the pending FDA clearance for the AYON's label expansion to include power liposuction [4][7] - Total revenue for Q3 2025 reached $12.9 million, a 12.1% increase compared to $11.5 million in the same period last year [7][9] Financial Performance - Surgical Aesthetics revenue for Q3 2025 was $11.1 million, up from $9.3 million in Q3 2024, reflecting a 19% increase [9][10] - OEM revenue decreased by 18% to approximately $1.8 million in Q3 2025 compared to $2.2 million in Q3 2024 [7][9] - Gross profit for Q3 2025 increased to $8.3 million, with a gross margin of 64.4%, up from 60.5% in the prior year [10][12] Operating Expenses and Losses - Operating expenses decreased by $1.5 million to $9.1 million in Q3 2025 compared to $10.6 million in Q3 2024 [11] - Net loss attributable to stockholders was $2.0 million in Q3 2025, an improvement from a net loss of $4.7 million in Q3 2024 [12][24] - Adjusted EBITDA loss decreased significantly to $0.1 million for Q3 2025, compared to $2.4 million for the same period in 2024 [13][31] Future Outlook - The company raised its total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million, up from the previous guidance of $50.0 million to $52.0 million [6][20] - Surgical Aesthetics revenue is expected to be between $43.0 million and $45.0 million for FY2025, compared to approximately $38.6 million reported for FY2024 [20] - The company plans to continue expanding the user base for AYON, which is expected to drive growth in single-use handpiece sales [4][6]

Apyx Medical (NasdaqGS:APYX) Conference Call Summary Company Overview - **Company**: Apyx Medical Corporation - **Event Date**: October 14, 2025 - **Key Product**: Apyx One Console, a body contouring system Industry Insights - **Market Context**: The surgical aesthetics market is evolving, particularly due to the rise of GLP-1 therapies for weight loss, leading to increased demand for body contouring solutions among post-weight loss patients [4][6] - **Market Size**: GLP-1 therapies are projected to exceed $100 billion by 2030, with 44% of users spending between $2,000 and $5,000 on aesthetic procedures, a 25% increase in spending [6] - **Patient Demographics**: 63% of GLP-1 users are new to aesthetics post-weight loss, indicating a growing patient population for plastic surgeons [6] Product Launch and Performance - **Product Launch**: Apyx One Console received approval in May 2025 and has undergone a successful soft launch with key surgeons across the U.S. [5][4] - **Sales Update**: Commercial sales began in September 2025, with ongoing sales in Q4 2025. A 510(k) submission for the power-assisted handpiece is expected to receive clearance in Q1 2026 [5][6] - **Technological Advancements**: The Apyx One Console integrates multiple technologies, including ultrasound-assisted liposuction and Renuvion for skin tightening, designed based on feedback from leading plastic surgeons [10][12] Clinical Insights - **Surgical Trends**: There has been a decline in liposuction procedures by 10.7%, while surgical lifts have increased by over 20%, reflecting the need for more complex surgical interventions for patients with lax skin [7][8] - **Patient Concerns**: 72% of GLP-1 users report loose skin as their primary concern, with 57% seeking treatment within six months post-weight loss [9] Feedback and Reception - **Surgeon Feedback**: Surgeons have expressed high satisfaction with the Apyx One Console, describing it as revolutionary and comparing it to luxury vehicles like Ferraris and Lamborghinis [13][14] - **Clinical Efficiency**: The integration of technologies in the Apyx One Console has led to improved surgical efficiency, with reduced procedure times and enhanced patient outcomes [32][51] Future Outlook - **Market Positioning**: Apyx Medical is well-positioned to capture growth in the surgical aesthetics market, particularly among post-weight loss patients seeking body contouring solutions [6][4] - **Anticipated Developments**: The upcoming launch of the power-assisted handpiece is expected to further enhance the capabilities of the Apyx One Console, attracting more surgeons and patients [65][66] Additional Insights - **Patient Experience**: The Apyx One Console aims to simplify the surgical process, reducing the need for multiple devices and improving the overall patient experience [21][22] - **Technological Trust**: Surgeons have shown a willingness to adopt the Apyx One Console based on the company's commitment to evidence-based medicine and the collaborative development process involving top surgeons [66][68] This summary encapsulates the key points discussed during the Apyx Medical conference call, highlighting the company's strategic positioning, product innovations, and the evolving landscape of the surgical aesthetics market.